MedTrace Logo

Trial of Lamivudine Treatment in HBeAg Negative Chronic Hepatitis B Patients (in Asia)

NCT00338780 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2006-10-30

No results posted yet for this study

Summary

The aim is to investigate whether Lamivudine 100mg daily is effective in the long term treatment of HBeAg negative chronic HBV infected patients with active liver disease in Asia

Conditions

Interventions

DRUG

Lamivudine/ Placebo 100mg daily

Sponsors & Collaborators

  • GlaxoSmithKline

    collaborator INDUSTRY

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Joseph JY Sung, PhD · Chinese University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-11-30
Completion
2005-01-31

Countries

  • China

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00338780 on ClinicalTrials.gov